Speratum Biopharma Inc

Speratum Biopharma, Inc. is a biotechnology company operating in Dover, Delaware. The company was founded in 2014 and has 12 employees. Speratum Biopharma focuses on the pre-clinical research and development of oligonucleotide therapeutics for the treatment of cancer. Their therapeutic platform utilizes proprietary technologies licensed from Baylor College of Medicine and boasts broad applicability. Speratum’s first therapeutic in pre-clinical development is a tumor suppressor targeting pancreatic, ovarian, and other cancers. This therapeutic combines a proprietary RNA interference (RNAi)-inducing mimic of miR-198, a naturally-occurring microRNA, with a novel Nano-in polymer-based delivery system that enables systemic and targeted delivery of nucleic acids both in vitro and in vivo. The company's innovative approach to cancer treatment leverages RNA interference and a proprietary polymer delivery system. This combination aims to provide a targeted and effective method for treating various types of cancer. For more information about Speratum Biopharma and its technologies, please contact the company at [email protected].